ReviewPharmaceutics2026
Transforming Cancer Care with Oncosomes: Insight into Biogenesis, Functional Role, and Therapeutic Potential.
Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular vesicle biomarkers: current status and future perspectives as novel tools in liquid biopsy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncosomes, a distinct subclass of extracellular vesicles released predominantly by tumor cells, have attracted increasing interest as potential carriers for targeted drug delivery in cancer research. Characterized by their large size (1-10 µm) and complex molecular cargo, including oncogenic proteins, nucleic acids, and lipids, oncosomes provide a biologically relevant platform for investigating tumor-associated communication and cargo transport. Preclinical studies suggest that oncosomes may enable tumor-associated delivery of therapeutic agents; however, evidence to date remains largely proof-of-concept and derived from in vitro and animal models. This review summarizes current knowledge on oncosome biogenesis and molecular composition; discusses their roles in cancer progression and metastasis; and critically evaluates existing methodologies for oncosome isolation, characterization, and cargo loading, including incubation, electroporation, sonication, freeze-thaw cycling, and transfection. Potential advantages such as cargo capacity and biological compatibility are discussed alongside key challenges, including vesicle heterogeneity, limited loading efficiency, large-scale manufacturing constraints, safety considerations, and regulatory uncertainty. Future perspectives focus on addressing these technical and translational barriers to support the systematic evaluation of engineered oncosomes as an experimental platform for personalized and precision-oriented cancer research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.